Comparison of the immunomodulatory effect of single MSC batches versus pooled MSC products.
Severe corticosteroid-refractory graft-versus-host-disease (GVHD) is a major non-relapse cause of mortality and morbidity after an allogeneic hematopoietic stem cell transplantation (allo-HSCT). One of the most promising treatment options is using advanced therapy medicinal products based on mesenchymal stem cells (MSCs) immunomodulation ability. The protocols of MSC application differ in many parameters including a source of MSC, a dose, a number of doses or way of preparation of the medicinal product. The process is limited by the need for laborious and expensive manufacturing processes fraught with batch-to-batch variability. In our study, we compared the immunomodulatory effects of different MSC batches versus pooled MSC, specifically the influence on lymphocyte proliferation, the metabolic activity, and the expression of activation markers on T cells. Our goal was to determine whether the effect depends on donor-to-donor heterogeneity and if pooling of MSCs could increase their immunomodulatory ability. All tested batches showed an immunomodulatory effect, with no significant differences between the groups. Our study suggests that immunosuppressive potential is comparable in single batches and pooled products, and the use of products got from individual donors is suitable to treat corticosteroid-refractory GVHD.
['Hejretová|L|L|', 'Čedíková|M|M|http://orcid.org/0000-0003-1505-5971', 'Dolejšová|M|M|', 'Vlas|T|T|', 'Jindra|P|P|http://orcid.org/0000-0002-8415-7069', 'Lysák|D|D|http://orcid.org/0000-0001-9391-4247', 'Holubová|M|M|http://orcid.org/0000-0002-5096-9659']
D049109:Cell Proliferation D002469:Cell Separation D002478:Cells, Cultured D018920:Coculture Techniques D006086:Graft vs Host Disease D018380:Hematopoietic Stem Cell Transplantation D006801:Humans D056747:Immunomodulation D008213:Lymphocyte Activation D045164:Mesenchymal Stem Cell Transplantation D059630:Mesenchymal Stem Cells D013601:T-Lymphocytes D014019:Tissue Donors
Immunomodulation Graft-versus-host disease Mesenchymal stromal cells